Skip to main content

Considerations for Clinical Use of Mesenchymal Stromal Cells

  • Living reference work entry
  • First Online:
Handbook of Stem Cell Therapy

Abstract

The clinical application of stem cells continues to fascinate the scientific and clinical communities. Despite the controversies surrounding this field, it is clear that stem cells have revolutionized regenerative medicine. Cell therapy is a progressively growing field that is moving fast from preclinical model development to clinical application. In this regard, outcomes obtained from clinical trials reveal the therapeutic potential of stem cell-based therapy that deals with unmet medical treatment for several disorders with no therapeutic alternatives. The application of stem cells in regenerative medicine is addressing a wide range of clinical conditions using various types of stem cells. Mesenchymal stromal cells (MSCs) have been established as promising candidate sources of universal donor cells for cell therapy due to their contributions to tissue and organ homeostasis, repair, and support by self-renewal and multi-differentiation, as well as by their anti-inflammatory, anti-proliferative, immunomodulatory, trophic, and pro-angiogenic properties. Various diseases have been successfully treated by MSCs in animal models. Additionally, hundreds of clinical trials related to the potential benefits of MSCs are in progress or have concluded satisfactorily. However, although all MSCs are considered suitable to exert these functions, dissimilarities have been found among MSCs derived from different tissues. The same levels of efficacy and desired outcomes have not always been achieved in the diverse studies that have been performed thus far. Therefore, collecting information regarding the characteristics of MSCs obtained from different sources and the influence of other medical and physiological conditions on MSCs is important for assuring the feasibility, safety, and efficacy of cell-based therapies. This chapter will update and discuss the state of the art in MSCs’ cell-based therapies and provide relevant information regarding factors to consider for the clinical application of MSCs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Institutional subscriptions

Abbreviations

Ad-MSCs:

Adipose tissue-derived MSCs

AGEs:

Advanced glycation end products

ATMPs:

Advanced therapy medicinal products

bFGF:

Basic fibroblast growth factor

BM-MSCs:

Bone marrow-derived MSCs

CAFs:

Cancer-associated fibroblasts

Cas9:

CRISPR-associated protein 9

CCL:

Chemokine (C-C motif) ligand

CFU-F:

Colony-forming unit fibroblast

CRISPR:

Clustered regularly interspaced short palindromic repeats

CXCL12:

C-X-C motif chemokine 12 (or SDF1)

Dkk-1:

Dickkopf-1

ECs:

Endothelial cells

EMA:

European Medicines Agency

ESCs:

Embryonic stem cells

EVs:

Extracellular vesicles

FBS:

Fetal bovine serum

FDA:

Food and Drug Administration

GM-CSF:

Granulocyte-macrophage colony-stimulating factor

GMP:

Good manufacturing practice

GPS:

Glycotransferase-programmed stereo substitution

GVHD:

Graft-versus-host diseases

GVL:

Graft-versus-leukemia

HCELL:

Hematopoietic cell E-selectin/L-selectin ligand

HGF:

Hepatocyte growth factor

HLA-DR:

Human leukocyte antigen-DR isotype

HLA-G5:

Human leukocyte antigen-G5

HSCT:

Hematopoietic stem cell transplantation

IBMIR:

Instant blood-mediated inflammatory reaction

ICAM-2:

Intercellular adhesion molecule 2

IDO:

Indoleamine-2,3-dioxygenase

IFN-γ:

Interferon-gamma

IGF-1:

Insulin-like growth factor 1

IL:

Interleukin

IL-1α:

Interleukin-1 alpha

IL-1β:

Interleukin-1 beta

iPSCs:

Induced pluripotent stem cells

ISCT:

International Society for Cellular Therapy

ITP:

Immune thrombocytopenic purpura

LFA-3:

Lymphocyte function-associated antigen 3 (or CD58)

MCP-1:

Monocyte chemoattractant protein 1

MHC-HLA:

Major histocompatibility complex-human leukocyte antigen

MMP-2:

Matrix metalloproteinase 2

MSCs:

Mesenchymal stromal cells

PAI-1:

Plasminogen activator inhibitor-1

PDGF:

Platelet-derived growth factor

PD-MSCs:

Placenta-derived MSCs

PGE-2:

Prostaglandin-E2

RA:

Rheumatoid arthritis

SDF-1:

Stromal cell-derived factor 1

SLE:

Systemic lupus erythematosus

SSc:

Systemic sclerosis

STC1:

Stanniocalcin-1

TALENs:

Transcription activator nucleases

TbRIII:

Type III TGF-β receptor

TGF-β:

Transforming growth factor beta

TNF-α:

Tumor necrosis factor alpha

tPA:

Tissue plasminogen activator

TRAIL:

TNF-related apoptosis-inducing ligand

Trx1:

Thioredoxin-1

TSG-6:

Tumor necrosis factor-stimulated gene-6

UCB-MSCs:

Umbilical cord-derived MSCs

VCAM-1:

Vascular cell adhesion protein 1

VEGF:

Vascular endothelial growth factor

ZFNs:

Zinc finger nucleases

References

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Abdelkrim Hmadcha .

Editor information

Editors and Affiliations

Section Editor information

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Singapore Pte Ltd.

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Hmadcha, A., Soria, B., Tejedo, J.R., Bedoya, F.J., Sempere-Ortells, J.M., Smani, T. (2022). Considerations for Clinical Use of Mesenchymal Stromal Cells. In: Haider, K.H. (eds) Handbook of Stem Cell Therapy. Springer, Singapore. https://doi.org/10.1007/978-981-16-6016-0_3-1

Download citation

  • DOI: https://doi.org/10.1007/978-981-16-6016-0_3-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-16-6016-0

  • Online ISBN: 978-981-16-6016-0

  • eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics